Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- NGM:POLAR
PolarCool Full Year 2023 Earnings: kr0.41 loss per share (vs kr1.07 loss in FY 2022)
PolarCool (NGM:POLAR) Full Year 2023 Results
Key Financial Results
- Revenue: kr1.98m (up 4.2% from FY 2022).
- Net loss: kr12.1m (flat on FY 2022).
- kr0.41 loss per share (improved from kr1.07 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PolarCool's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 6 warning signs for PolarCool you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether PolarCool is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:POLAR
PolarCool
PolarCool AB (publ), a medical device company, develops, markets, and sells products for sports medicine.
Mediocre balance sheet and slightly overvalued.